# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k063322   
B. Purpose for Submission: New Device   
C. Analyte: Transferrin   
D. Type of Test: Quantitative, immunonephelometry   
E. Applicant: Dade Behring, Inc.   
F. Proprietary and Established Names: Dimension Vista™ Transferrin Flex $\textsuperscript { \textregistered }$ reagent cartridge Dimension Vista™ Protein 1 Calibrator Dimension Vista™ Protein 1 Control L Dimension Vista™ Protein 1 Control M Dimension Vista™ Protein 1 Control H

# G. Regulatory Information:

1. Regulation section: 21CFR $\ S 8 6 6 . 5 8 8 0 \cdotp$ - Transferrin immunological test system 21CFR $\ S 8 6 2 . 1 1 5 0 \cdot$ - Calibrator 21CFR $\ S 8 6 2 . 1 6 6 0 \cdot$ - Quality control material

2. Classification: Class II

3. Product Code: DDG - Transferrin, antigen, antiserum, control JIX - Calibrator, multi-analyte mixture JJY - Multi-analyte controls, all kinds (assayed and unassayed)

4. Panel: Immunology (82)

# H. Intended Use:

1. Intended use(s): Transferrin Flex $\textsuperscript { \textregistered }$ reagent cartridge: The TRF method is an in vitro diagnostic test for the quantitative determination of transferrin in human serum, heparinized plasma or EDTA plasma on the Dimension Vista™ System. Measurements of transferrin aid in the diagnosis of malnutrition, acute inflammation, infection, and iron deficiency anemia. Protein 1 Calibrator: PROT1 CAL is an in vitro diagnostic product for the calibration of the C3 complement (C3), C4 complement (C4), Immunoglobulin A (IGA), Immunoglobulin G (IGG), Immunoglobulin M (IGM), Prealbumin (PREALB) and Transferrin (TRF) methods on the Dimension Vista™ System. Protein 1 Controls L, M and H: PROT 1 CON L, M, and H are assayed intralaboratory quality controls for assessment of precision and analytical bias in the determination of C3 complement (C3), C4 complement (C4), Immunoglobulin A (IGA), Immunoglobulin G (IGG), Immunoglobulin M (IGM), Prealbumin (PREALB) and Transferrin (TRF) methods on the Dimension Vista™ System.

2. Indication(s) for use: Same as intended use.   
3. Special condition for use statement(s): Prescription use only.   
4. Special instrument Requirements: Dimension Vista™ System

I. Device Description:

Dimension Vista ™ Flex $\textsuperscript { \textregistered }$ regent cartridge (TRF): TRF reagent consists of a Reaction buffer and an antiserum to polyclonal rabbit antiserum to human transferrin.   
Dimension Vista ™ Protein 1 Calibrator:   
PROT1 CAL is a multi-analyte, liquid, human serum based product containing C3, C4, IgA, IgG, IgM, prealbumin and transferrin.   
Dimension Vista ™ Protein 1 Control L and H:   
PROT1 CON L, M and H are multi-analyte, liquid, human serum based product containing C3, C4, IgA, IgG, IgM, prealbumin and transferrin.

J. Substantial Equivalence Information:

1. Predicate device name(s) and 510(k) numbers: Dade Behring N Antisera to Human Transferrin assay (k053075) N Protein Standard SL (k012470) N/T Protein Control SL (k012468)   
2. Comparison with predicate:

# Dimension Vista™ Transferrin Flex $^ \mathrm { \textregistered }$ regent cartridge

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">For the quantitativedetermination oftransferrin in humanserum, heparinizedplasma, or EDTA plasmaon the Dimension VistaTMSystem.</td><td colspan="1" rowspan="1">For the quantitative invitro determination oftransferrin andhaptoglobulin in humanserum, heparinized andEDTA plasma, as well asof transferrin in humanurine by means ofimmunonephelometry onthe BN Systems.</td></tr><tr><td colspan="1" rowspan="1">Indications for Use</td><td colspan="1" rowspan="1">Measurements are usedas an aid in the diagnosisof malnutrition, acuteinflammation, infection,and iron deficiencyanemia.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Method</td><td colspan="1" rowspan="1">Immunonephelometry</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Measurement type</td><td colspan="1" rowspan="1">Quantitative</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Capture Antibody</td><td colspan="1" rowspan="1">Rabbit polyclonal</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Measuring Range</td><td colspan="1" rowspan="1">0.35 to 5.6 g/L</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reference Interval(Expected values)</td><td colspan="1" rowspan="1">2.0 - 3.6 g/L</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Storage: Unopened</td><td colspan="1" rowspan="1">2-8°C</td><td colspan="1" rowspan="1">Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Instrument system</td><td rowspan=1 colspan=1>Dimension Vista®System</td><td rowspan=1 colspan=1>BN ProSpec® System</td></tr><tr><td rowspan=1 colspan=1>Matrices</td><td rowspan=1 colspan=1>Serum, lithium heparinplasma, EDTA plasma</td><td rowspan=1 colspan=1>Serum, lithium heparinplasma, EDTA plasmaand urine.</td></tr><tr><td rowspan=1 colspan=1>Stability: Open</td><td rowspan=1 colspan=1>21 days 2-8°C</td><td rowspan=1 colspan=1>4 weeks 2-8°C</td></tr><tr><td rowspan=1 colspan=1>Stability: On board</td><td rowspan=1 colspan=1>Unopened 90 days</td><td rowspan=1 colspan=1>5 days 8 hr/day for 5 mlvials; 3 days for 2mlvials</td></tr></table>

# Dimension Vista™ Protein 1 Calibrator

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>PROT1 CAL is an invitro diagnostic productfor the calibration of theC3 Complement (C3), C4Complement (C4),Immunoglobulin A(IGA), ImmunoglobulinG (IGG),Immunoglobulin M(IGM), Prealbumin(PREALB), andTransferrin (TRF)methods on theDimension VistaTMSystem</td><td rowspan=1 colspan=1>For establishment ofreference curves forspecificimmunonephelometricdeterminations</td></tr><tr><td rowspan=1 colspan=1>Composition</td><td rowspan=1 colspan=1>Pooled human sera</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent Preparation</td><td rowspan=1 colspan=1>Liquid, Ready-to-use</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>ERM®-DA470 (CRM470) L, M, and H</td><td rowspan=1 colspan=1>Same</td></tr></table>

Dimension Vista ™ Protein 1 Control L, M and H   

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1>7 analytes</td><td rowspan=1 colspan=1>26 analytes</td></tr><tr><td rowspan=1 colspan=1>Instrument system</td><td rowspan=1 colspan=1>Dimension Vista®System</td><td rowspan=1 colspan=1>BN Systems</td></tr><tr><td rowspan=1 colspan=1>Stability: Open</td><td rowspan=1 colspan=1>9 days 2-8°C</td><td rowspan=1 colspan=1>14 days 2-8°C</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Assayed intra-laboratoryquality controls for theassessment of precisionand analytical bias in thedetermination of specificassays</td><td rowspan=1 colspan=1>Assayed controls foraccuracy and precision inthe quantitativedetermination of specificanalytes</td></tr><tr><td rowspan=1 colspan=1>Composition</td><td rowspan=1 colspan=1>Pooled human sera</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent Preparation</td><td rowspan=1 colspan=1>Liquid, Ready-to-use</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1>7 analytes</td><td rowspan=1 colspan=1>26 analytes</td></tr><tr><td rowspan=1 colspan=1>Instrument system</td><td rowspan=1 colspan=1>Dimension VistaTMSystem</td><td rowspan=1 colspan=1>BN Systems and theTurbiTime System</td></tr><tr><td rowspan=1 colspan=1>Concentration Range</td><td rowspan=1 colspan=1>Low, medium and High</td><td rowspan=1 colspan=1>Low and High</td></tr><tr><td rowspan=1 colspan=1>Stability Open</td><td rowspan=1 colspan=1>9 days 2-8°C</td><td rowspan=1 colspan=1>14 days 2-8°C</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI Evaluation of Precision Performance of Clinical Devices; Approved Guideline: EP5-A2, CLSI Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline EP9-A2, CLSI Interference Testing in Clinical Chemistry; Approved Guideline EP7-A2.

L. Test Principle:

Proteins contained in human body fluids form immune complexes in an immunochemical reaction with specific antibodies. These complexes scatter a beam of light passed through the sample. The intensity of the scattered light is proportional to the concentration of the respective protein in the sample. The result is evaluated by comparison with a standard of known concentration.

# M. Performance Characteristics (if/when applicable):

Analytical performance: a. Precision/Reproducibility: Precision testing was done in accordance with CLSI Approved Guideline EP5-A2. Two samples derived from serum pools and two samples derived from plasma pools representing TRF concentrations that span the measuring range, and the PROT1 CON L, M and H were analyzed in duplicate, for 20 days, two runs per day. The repeatability and within-lab standard deviations (SD) and percent coefficient of variation $( \% C V )$ were calculated by the analysis of variance method. Repeatability imprecision was $< 3 . 3 \%$ , and Within-Lab irreproducibility was $< 3 . 5 \%$ .

<table><tr><td rowspan=2 colspan=1>Material</td><td rowspan=2 colspan=1>Mean g/L</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Within-Lab</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>PROT2 CON L</td><td rowspan=1 colspan=1>1.99</td><td rowspan=1 colspan=1>0.047</td><td rowspan=1 colspan=1>2.36</td><td rowspan=1 colspan=1>0.057</td><td rowspan=1 colspan=1>2.85</td></tr><tr><td rowspan=1 colspan=1>PROT1CON M</td><td rowspan=1 colspan=1>2.66</td><td rowspan=1 colspan=1>0.058</td><td rowspan=1 colspan=1>2.18</td><td rowspan=1 colspan=1>0.083</td><td rowspan=1 colspan=1>3.13</td></tr><tr><td rowspan=1 colspan=1>PROT2CON H</td><td rowspan=1 colspan=1>3.97</td><td rowspan=1 colspan=1>0.093</td><td rowspan=1 colspan=1>2.35</td><td rowspan=1 colspan=1>0.112</td><td rowspan=1 colspan=1>2.82</td></tr><tr><td rowspan=1 colspan=1>Serum pool</td><td rowspan=1 colspan=1>1.53</td><td rowspan=1 colspan=1>0.023</td><td rowspan=1 colspan=1>1.53</td><td rowspan=1 colspan=1>0.031</td><td rowspan=1 colspan=1>1.99</td></tr><tr><td rowspan=1 colspan=1>Serumpool</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>0.087</td><td rowspan=1 colspan=1>2.01</td><td rowspan=1 colspan=1>0.112</td><td rowspan=1 colspan=1>2.60</td></tr><tr><td rowspan=1 colspan=1>Plasma pool</td><td rowspan=1 colspan=1>0.79</td><td rowspan=1 colspan=1>0.026</td><td rowspan=1 colspan=1>3.27</td><td rowspan=1 colspan=1>0.027</td><td rowspan=1 colspan=1>3.46</td></tr><tr><td rowspan=1 colspan=1>Plasma pool</td><td rowspan=1 colspan=1>2.55</td><td rowspan=1 colspan=1>0.036</td><td rowspan=1 colspan=1>1.41</td><td rowspan=1 colspan=1>0.060</td><td rowspan=1 colspan=1>2.37</td></tr></table>

b. Linearity/assay reportable range:

Linearity across the range was confirmed by testing a calibrator with a high concentration of transferrin. The calibrator was serially diluted in 5, approximately two fold increments (measuring range from 0.28 to $6 . 9 5 \ \mathrm { g / L } )$ ). Each dilution was tested in replicates of three. Data were analyzed using linear regression analysis: regression analysis of theoretical concentration versus measured concentration produced the following results:

<table><tr><td>Slope</td><td>Y-Intercept g/L</td><td>Correlation Coefficient</td><td>n</td></tr><tr><td>1.038</td><td>-0.045</td><td>0.999</td><td>15</td></tr></table>

Recovery testing with European reference material ERM $\mathrm { ( \mathord { \mathrm { { R } } } ) - D A } 4 7 0 ^ { \ast }$ was performed with 5 replicates of a TRF sample $2 . 4 5 \ \mathrm { g / L }$ . Results ranged from 97.1 - $. 1 0 0 . 2 \%$ with a mean recovery of $9 8 . 8 \%$ .

c. Traceability (controls, calibrators, or method):

Calibration material values were referenced to the European reference material ERM $\mathrm { ( \mathord { \mathrm { { R } } } ) - D A } 4 7 0 ^ { \ast }$ .

d. Detection limit:

Analytical sensitivity was determined by assaying analyte-free System Diluent 20 times and determining the mean value plus two SDs: $0 . 0 6 2 \ : \mathrm { g / L }$ .

e. Analytical specificity:

i. Interference Studies Interference testing was performed according to CLSI EP7-A2, to determine the effect of various endogenous and exogenous substances on the Dimension Vista™ TRF assay. For the following interferents, the percent bias was determined by testing a control samples without the interferent and comparing it to the value obtained from a test sample to which the potential interferent was added: bilirubin (conjugated and unconjugated, $6 0 \mathrm { m g / d L } )$ , hemoglobin ( $\mathrm { 1 0 0 0 m g / d L } )$ , creatinine $\mathrm { 3 0 m g / d L } )$ , albumin $( 6 ~ \mathrm { g } / \mathrm { d L } )$ , urea $( 5 0 0 \mathrm { m g / d L } )$ , cholesterol $( 5 0 0 \mathrm { m g / d L } )$ , uric acid $( 2 0 \mathrm { m g / d L } )$ . Minimal interference $( < 8 \% )$ was observed. Interference by

triglycerides (native and clarified) was tested on 5 test samples containing a known amount of triglycerides and comparing results from the same sample after centrifugation. Interference was less than $6 \%$ . Samples containing rheumatoid factor $( > 5 0 0 \mathrm { I U / m l } )$ or total protein ${ \tt > } 1 2 0 \ \mathrm { g / L }$ were mixed 1:1 with TRF concentrations and $\%$ recovery was compared to samples without RF using 5 replicates. No interference was observed up to $3 5 0 \mathrm { \ I U / m l }$ and $8 8 ~ \mathrm { g / L }$ TP.

Additionally, 41 potentially interfering drugs were also assayed and shown to exhibit minimal interference $( < 1 0 \% )$ .

ii. Cross-reactivity with autoimmune antibodies common to other systemic autoimmune diseases was not tested.

iii. Antigen Excess: The effect of antigen excess was evaluated using a serum sample with a high concentration of transferrin (above the assay range). No effect was seen up to $9 . 4 6 \ \mathrm { g / L }$ . Samples whose values exceed $5 . 6 \mathrm { g / L }$ using the initial 1:20 dilution are reported as “exceeds assay range” to alert the user to repeat the assay using a higher dilution.

f. Assay cut-off: See Expected values

2. Comparison studies:

a. Method comparison with predicate device: The Dimension Vista™ TR assay was compared to the Dade Behring N Antisera to Human Transferrin assay on the BN ProSepc $\textsuperscript { \textregistered }$ System by evaluating serum and plasma samples with concentrations ranging from 0.79 to $5 . 4 3 \ \mathrm { g / L }$ . Regression analysis of these results yielded the following statistics:

<table><tr><td>Comparative Method</td><td>Slope (95%CI)</td><td>Y-Intercept (g/L) (95%CI)</td><td>Correlation Coefficient</td><td>n</td></tr><tr><td>N Antisera to Human Transferrin on the BN ProSpec </td><td>1.087 (1.071 to 1.102)</td><td>0.060 (-0.088 to -0.032)</td><td>0.992</td><td>180</td></tr></table>

b. Matrix comparison:

Ten matched samples of serum, EDTA, lithium heparin and sodium heparin plasma containing concentrations of transferrin spanning the measuring range (0.37 to $4 . 9 2 \ \mathrm { g / L }$ ), were assayed and compared. Regression analysis showed no significant bias between the four matrices and yielded the following information:

<table><tr><td colspan="2">% Recovery statistics for anticoagulant-plasma vs. serum</td><td>Slope (95%CI)</td><td>Y-Intercept (g/L)</td><td>Correlation Coefficient</td><td>n</td></tr><tr><td>Lithium heparin plasma</td><td>Mean = -0.5% (Range = -4.5%-4.4%)</td><td>0.98 (0.956-1.01)</td><td>0.03</td><td>0.998</td><td>10</td></tr><tr><td>Sodium heparin plasma</td><td>Mean = 0.8% (Range = -2.7%-5.0%)</td><td>1.02 (0.987-1.05)</td><td>-0.02</td><td>0.998</td><td>10</td></tr><tr><td>EDTA plasma</td><td>Mean = -2.9% (Range = -7.9%-1.5%)</td><td>0.95 (0.920-0.98)</td><td>0.03</td><td>0.998</td><td>10</td></tr></table>

3. Clinical studies:

a. Clinical sensitivity: Not provided   
b. Clinical specificity: Not provided   
c. Other clinical supportive data (when a and b are not applicable): Not applicable.

4. Clinical cut-off: See assay range

5. Expected values/Reference range:

A reference range for normal transferrin levels is provided and supported by additional testing using the Dimension Vista™ TRF assay supplied by sponsor. Results support the reference interval $2 . 0 { - } 3 . 6 \mathrm { g / L }$ . This reference interval applies to serum samples from healthy adults.

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.